You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
When oral therapy is not feasible, and the strength, form and route of administration of the drug
reasonably lend the preparation to the treatment of the condition, SOLU-CORTEF powder for
injection is indicated for intravenous or intramuscular use in the following conditions:, 1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is
the drug of choice; synthetic analogues may be used in conjunction with
mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
Acute adrenocortical insufficiency
(hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements
may be necessary, particularly when synthetic analogues are used).
Preoperatively and in the event of serious trauma or illness, in patients with known
adrenal insufficiency or when adrenocortical reserve is doubtful
Shock unresponsive to conventional therapy if adrenocortical insufficiency exists
or is suspected
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcaemia associated with cancer., 2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode
or exacerbation) in:
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may
require low dose maintenance therapy)
Acute and subacute bursitis
Epicondylitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Psoriatic arthritis
Ankylosing spondylitis., 3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis., 4. Dermatological Diseases
Pemphigus
Severe erythema multiforme (Stevens-Johnson Syndrome)
Exfoliative dermatitis
Bullous dermatitis herpetiformis
Severe seborrhoeic dermatitis
Severe psoriasis
Mycosis fungoides., 5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment in:
Bronchial asthma
Drug hypersensitivity reactions
Contact dermatitis
Urticarial transfusion reactions
Atopic dermatitis
Serum sickness
Acute noninfectious laryngeal oedema (adrenaline is the drug of first choice)., 6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
Herpes zoster ophthalmicus
Iritis, iridocyclitis
Chorioretinitis
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
Anterior segment inflammation
Allergic conjunctivitis
Allergic corneal marginal ulcers
Keratitis., 7. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis (systemic therapy)
Regional enteritis (systemic therapy)., 8. Respiratory Diseases
Symptomatic sarcoidosis
Loefflers syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with
appropriate antituberculous chemotherapy
Aspiration pneumonitis.,9. Haematological Disorders
Acquired (autoimmune) haemolytic anaemia
Erythroblastopenia (RBC anaemia)
Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is
contraindicated)
Secondary thrombocytopenia in adults
Congenital (erythroid) hypoplastic anaemia., 10. Neoplastic Diseases
For palliative management of:
Leukaemias and lymphomas in adults
Acute leukaemia in childhood., 11. Oedematous States
To induce diuresis or remission of proteinuria in the nephrotic syndrome, without
uraemia, of the idiopathic type or that due to lupus erythematosus., 12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used
concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurological or myocardial involvement.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
When oral therapy is not feasible, and the strength, form and route of administration of the drug
reasonably lend the preparation to the treatment of the condition, SOLU-CORTEF powder for
injection is indicated for intravenous or intramuscular use in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is
the drug of choice; synthetic analogues may be used in conjunction with
mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
Acute adrenocortical insufficiency
(hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements
may be necessary, particularly when synthetic analogues are used).
Preoperatively and in the event of serious trauma or illness, in patients with known
adrenal insufficiency or when adrenocortical reserve is doubtful
Shock unresponsive to conventional therapy if adrenocortical insufficiency exists
or is suspected
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcaemia associated with cancer.
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode
or exacerbation) in:
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may
require low dose maintenance therapy)
Acute and subacute bursitis
Epicondylitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Psoriatic arthritis
Ankylosing spondylitis.
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis.
4. Dermatological Diseases
Pemphigus
Severe erythema multiforme (Stevens-Johnson Syndrome)
Exfoliative dermatitis
Bullous dermatitis herpetiformis
Severe seborrhoeic dermatitis
Severe psoriasis
Mycosis fungoides.
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment in:
Bronchial asthma
Drug hypersensitivity reactions
Contact dermatitis
Urticarial transfusion reactions
Atopic dermatitis
Serum sickness
Acute noninfectious laryngeal oedema (adrenaline is the drug of first choice).
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
Herpes zoster ophthalmicus
Iritis, iridocyclitis
Chorioretinitis
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
Anterior segment inflammation
Allergic conjunctivitis
Allergic corneal marginal ulcers
Keratitis.
7. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis (systemic therapy)
Regional enteritis (systemic therapy).
8. Respiratory Diseases
Symptomatic sarcoidosis
Loefflers syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with
appropriate antituberculous chemotherapy
Aspiration pneumonitis.
9. Haematological Disorders
Acquired (autoimmune) haemolytic anaemia
Erythroblastopenia (RBC anaemia)
Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is
contraindicated)
Secondary thrombocytopenia in adults
Congenital (erythroid) hypoplastic anaemia.
10. Neoplastic Diseases
For palliative management of:
Leukaemias and lymphomas in adults
Acute leukaemia in childhood.
11. Oedematous States
To induce diuresis or remission of proteinuria in the nephrotic syndrome, without
uraemia, of the idiopathic type or that due to lupus erythematosus.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used
concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurological or myocardial involvement.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
When oral therapy is not feasible, and the strength, form and route of administration of the drug
reasonably lend the preparation to the treatment of the condition, SOLU-CORTEF powder for
injection is indicated for intravenous or intramuscular use in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is
the drug of choice; synthetic analogues may be used in conjunction with
mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).
Acute adrenocortical insufficiency
(hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements
may be necessary, particularly when synthetic analogues are used).
Preoperatively and in the event of serious trauma or illness, in patients with known
adrenal insufficiency or when adrenocortical reserve is doubtful
Shock unresponsive to conventional therapy if adrenocortical insufficiency exists
or is suspected
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcaemia associated with cancer.
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode
or exacerbation) in:
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may
require low dose maintenance therapy)
Acute and subacute bursitis
Epicondylitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Psoriatic arthritis
Ankylosing spondylitis.
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis.
4. Dermatological Diseases
Pemphigus
Severe erythema multiforme (Stevens-Johnson Syndrome)
Exfoliative dermatitis
Bullous dermatitis herpetiformis
Severe seborrhoeic dermatitis
Severe psoriasis
Mycosis fungoides.
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of
conventional treatment in:
Bronchial asthma
Drug hypersensitivity reactions
Contact dermatitis
Urticarial transfusion reactions
Atopic dermatitis
Serum sickness
Acute noninfectious laryngeal oedema (adrenaline is the drug of first choice).
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye, such as:
Herpes zoster ophthalmicus
Iritis, iridocyclitis
Chorioretinitis
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
Anterior segment inflammation
Allergic conjunctivitis
Allergic corneal marginal ulcers
Keratitis.
7. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis (systemic therapy)
Regional enteritis (systemic therapy).
8. Respiratory Diseases
Symptomatic sarcoidosis
Loefflers syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with
appropriate antituberculous chemotherapy
Aspiration pneumonitis.
9. Haematological Disorders
Acquired (autoimmune) haemolytic anaemia
Erythroblastopenia (RBC anaemia)
Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is
contraindicated)
Secondary thrombocytopenia in adults
Congenital (erythroid) hypoplastic anaemia.
10. Neoplastic Diseases
For palliative management of:
Leukaemias and lymphomas in adults
Acute leukaemia in childhood.
11. Oedematous States
To induce diuresis or remission of proteinuria in the nephrotic syndrome, without
uraemia, of the idiopathic type or that due to lupus erythematosus.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used
concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurological or myocardial involvement.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
